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Abstract
Background: Endemic Burkitt’s lymphoma (BL) is an extranodal tumor appearing predominantly in the jaw in
younger children while abdominal tumors predominate with increasing age. Previous studies have identified
elevated levels of antibodies to Plasmodium falciparum schizont extracts and Epstein-Barr virus (EBV) viral capsid
antigens (VCA) in endemic BL relative to malaria exposed controls. However, these studies have neither determined
if there were any differences based on the site of clinical presentation of the tumor nor examined a broader panel
of EBV and P. falciparum antigens.
Methods: We used a suspension bead Luminex assay to measure the IgG levels against EBV antigens, VCA, EAd,
EBNA-1 and Zta as well as P. falciparum MSP-1, LSA-1, and AMA-1 antigens in children with BL (n = 32) and in
population-based age-and sex-matched controls (n = 25) from a malaria endemic region in Western Kenya with
high incidence of BL. EBV viral load in plasma was determined by quantitative PCR.
Results: Relative to healthy controls, BL patients had significantly increased anti-Zta (p = 0.0017) and VCA IgG
levels (p < 0.0001) and plasma EBV viral loads (p < 0.0001). In contrast, comparable IgG levels to all P. falciparum
antigens tested were observed in BL patients compared to controls. Interestingly, when we grouped BL patients
into those presenting with abdominal tumors or with jaw tumors, we observed significantly higher levels of anti-
Zta IgG levels (p < 0.0065) and plasma EBV viral loads (p < 0.033) in patients with abdominal tumors compared to
patients with jaw tumors.
Conclusion: Elevated antibodies to Zta and elevated plasma EBV viral load could be relevant biomarkers for BL
and could also be used to confirm BL presenting in the abdominal region.
Background
Endemic Burkitt’s lymphoma (BL) is the most common
pediatric cancer in areas that experience stable Plasmo-
dium falciparum transmission, and both Epstein-Barr
virus infection (EBV) and holoendemic P. falciparum
are thought to be etiologically linked to this B cell neo-
plasm [1-4]. BL is an aggressive extranodal B cell lym-
phoma that can present in a number of different sites
including jaw, abdomen, central nervous system, thyroid
gland, orbital, and breast or a combination of these
areas [5,6]. However, jaw and abdominal tumors are the
most common sites of presentation. Interestingly, there
are different epidemiologic patterns associated with chil-
dren presenting with jaw compared to abdominal
tumors. For example, while the median age of onset is 6
to 7 years for BL [7,8], jaw tumors are associated with a
younger age of presentation and more frequently found
in males, while abdominal tumors are common in older
children, and there is a more equal distribution among
males and females [6]. Despite the fact that endemic BL* Correspondence: rochforr@upstate.edu
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has several distinct clinical pictures, most studies have
looked at endemic BL as a single clinical entity.
The EBV life cycle comprises both lytic and latent
phases, both of which play a role in the pathogenesis of
EBV-associated malignancies, and induce different anti-
body responses [4,9]. EBV nuclear antigen (EBNA)-1 is
a latent antigen and is the only latent antigen consis-
tently expressed in BL tumors [10]. The EBV immediate
early lytic transcript BZLF1 which encodes the Zta pro-
tein can also be detected in a subset of BL tumors
[11,12] but whether elevated levels of antibodies against
Zta occur in children with BL is unknown. Two addi-
tional lytic antigens, viral capsid antigen (VCA) and
early antigen (EAd) have been used as serologic markers
of past EBV infection (e.g. VCA IgG) or viral reactiva-
tion (e.g. EAd IgG) [13]. Seminal studies in Uganda
showed that elevated titers of IgG against VCA were a
prognostic risk factor for BL development [14]. In addi-
tion, two recent case control studies in Uganda and
Malawi have found that children with BL are more likely
to have elevated antibody titers against VCA as com-
pared to controls [8,15]. These same studies also
reported elevated IgG antibody titers against P. falci-
parum schizont extracts in BL patients compared to
controls [8,15].
Until recently, measurement of pathogen-specific anti-
bodies was done with indirect immunofluorescence
assays or ELISA assays. These assays have the disadvan-
tage of allowing the measurement of only one antibody:
antigen complex per sample, which can otherwise
restrict the study of antibodies to multiple proteins
when sample volumes are limited. In order to overcome
this problem, multiplexed serology has recently been
developed for the study of antibodies to multiple anti-
gens within the same sample [16-18]. This assay can
analyze more than 100 analytes simultaneously from a
small sample volume enabling not only mass screening
of several antigens, but also studies in pediatric popula-
tions with limited sample volumes [17,18]. In addition,
this assay is less laborious and has fewer reaction steps
compared to the traditional ELISA [17] and the results
are highly reproducible [18]. We have recently devel-
oped a Luminex-based suspension bead assay, allowing
the determination of levels of IgG to four different EBV
antigens (EBNA, VCA, EAd and Zta) within the same
sample [16]. In this study, we used this technology to
enable more detailed study of antibody responses to an
increased panel of antigens in BL patients in an age-and
sex-matched controls living in a region where the risk
of BL is high [7]. The panel included P. falciparum
blood stage antigens (apical merozoite antigen (AMA)-1,
merozoite surface protein (MSP)-1 that were specific for
two strains of P. falciparum (3D7 and FV0) and a liver
stage antigen (LSA)-1, in addition to the earlier
mentioned EBV antigens. In addition, we also measured
EBV viral load in the plasma. We report differences in
both EBV serology and viral load profiles in children
with BL compared to control children with the unex-
pected finding that the clinical presentation of the
tumor correlated with levels of EBV Zta antibody and
plasma viral load.
Results
Study participant demographic characteristics
Children with endemic BL were recruited at admission
to Nyanza Provincial General Hospital (NPGH), the
major referral hospital for cancer treatment in Nyanza
province, Kenya. Children admitted to this hospital for
reasons other than cancer typically are from Kisumu
city. However, children with BL tend to come from
rural areas [7] and this was also true in the current
study. Therefore, our control population for this study
was from a rural area with high BL incidence and per-
sistent P. falciparum malaria transmission [7]. The
demographic and clinical characteristics of the study
participants are presented in Table 1. There were 32
children with BL and 25 controls frequency matched for
age and gender. The mean age of the control children
was 7.6 years and the mean age of the BL patients was
7.5 years. There were 21 male and 11 female children
with BL (66% male) and 16 males and 9 females (64%
male) in the control group of children. Of the BL
patients, there were 14 that exclusively presented with
tumor in the jaw and 16 that had only abdominal
tumors. In addition, there was 1 patient that had both
jaw and abdominal tumors and 1 patient with a lower
left limb tumor. When the BL patients were stratified
into clinical groups based on site of tumor presentation,
children presenting with jaw tumors were younger
[mean age, 5.6 years (IQR, 3.8-6.5)] than those present-
ing with abdominal tumors [mean age, 9.2 years (IQR,
6.3-11.00)] (p = 0.0018). Elevated serum lactate dehydro-
genase (LDH) is used clinically as a marker of overall
tumor burden [19]. Interestingly, BL patients with
abdominal tumors had significantly higher LDH levels
compared to patients with facial tumors (p = 0.0394).
BL patients and controls from malaria endemic region
have comparable levels of IgG against P. falciparum
antigens
To assess antibody levels to a broad panel of purified P.
falciparum antigens, we used a Luminex bead-based
array assay to measure IgG specific for 3 different
malaria antigens: AMA-1, MSP-1 and LSA-1. In addi-
tion, we analyzed AMA-1 and MSP-1 antigens derived
from 2 different known circulating strains of P. falci-
parum, the 3D7 and FVO strains. We detected antibo-
dies against the malaria antigens tested in all the
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patients and controls (Fig. 1). Remarkably, the relative
levels of IgG against all P. falciparum antigens tested
were comparable between BL patients and controls and
no significant differences were detected. Sixty-eight per-
cent of the controls had P. falciparum parasites in their
blood while only 13% of the BL patients were P. falci-
parum positive (Table 1). However, most children pre-
senting with BL at NPGH have been referred from
another hospital, and in most cases it was reported that
these patients have been treated with anti-malarial drugs
prior to admission at NPGH.
BL patients have increased EBV-specific Zta and VCA IgG
levels compared to the controls
We next determined if there were differences in the
EBV-specific IgG between BL patients and age-and gen-
der-matched controls. We measured IgG specific for the
EBV latent antigen, EBNA-1, and the EBV lytic antigens,
Zta, EAd, and VCA using well characterized synthetic
peptides as the target antigen in our multiplex assay
[16,20,21]. We found significantly higher levels of Zta
and VCA-specific IgG levels in BL patients compared to
controls (p < 0.0001 and p = 0.0017, respectively), while
the levels of EBNA-1 and EAd-specific IgG levels were
comparable between the two groups (p = 0.3382 and
p = 0.5046, respectively) (Fig. 2).
Children with abdominal tumors have higher levels of
Zta-specific IgG antibodies compared to children with jaw
tumors
To investigate if there were differences in the median
levels of EBV-specific IgG antibodies among BL patients
presenting with distinct clinical features, we stratified
the study population into BL patients presenting exclu-
sively with jaw tumors (n = 14) and those presenting
exclusively with abdominal tumors (n = 16) and com-
pared these to the controls (n = 25). The two patients
presenting with both jaw and abdominal tumors and the
patient presenting with a tumor in the lower limb were
excluded from this analysis. We observed elevated levels
of Zta-specific IgG antibodies in BL patients presenting
with abdominal tumors compared to those presenting
with jaw tumors (p = 0.0065). However, there were not
any significant differences of VCA, EAd, or EBNA1-spe-
cific IgG between patients presenting with jaw tumors
compared to those presenting with abdominal tumors
(Fig. 3).
EBV viral load in plasma is higher in patients with
abdominal tumors compared to jaw tumors
Other studies have identified elevated EBV viral loads in
plasma from patients with nasopharyngeal carcinoma or
EBV-associated Hodgkin’s disease [22,23]. To determine
if there were elevated plasma viral loads in BL patients
relative to age-and gender-matched controls, we mea-
sured EBV levels in plasma by Q-PCR. As shown in Fig.
4A, EBV DNA was readily detected in the plasma in 30
out of 32 (94%) of BL patients. In contrast, only 6/25
(24%) of the controls had detectable levels of EBV in the
plasma. Interestingly, the viral loads in the six control
samples with detectable levels of EBV in the plasma
were comparable to the levels in BL patients (medians,
4.105 log copies/ml versus 3.860 log copies/ml, respec-
tively, p = 0.1018).
When we compared EBV viral load in plasma from
BL patients with jaw tumors to BL patients with
abdominal tumors, we observed significantly higher
levels of EBV in plasma from BL patients presenting
with abdominal tumors compared to those presenting
with jaw tumors (p = 0.0337) (Fig. 4B). Elevated viral
load in the plasma could be due to increased release of
viral DNA from tumor cells due to apoptosis or necro-
sis of tumor cells, and not necessarily linked to elevated
anti-Zta and VCA IgG levels. To determine if Zta and
VCA IgG antibody levels correlated with EBV viral load,
we did a Spearman correlation and found that Zta-spe-
cific IgG levels were positively correlated with plasma
EBV viral loads in BL tumors (r = 0.3825, p = 0.0307)
while there was no correlation with VCA IgG levels
(r = -0.0972, p = 0.6093).
Table 1 The demographic and clinical characteristics of the study participants
Parameters Controls
(n = 25)
BL
(n = 32)
P valuea BL with abdominal
(n = 16)
BL with jaw
(n = 14)
P valuea
Mean age years [range]* 7.6[5.5-10] 7.5[5-11] n.s. 9.2[6.3-11] 5.6[3.8-6.50] 0.0018
Gender
n (% male)
16(64) 21(66) n.s. 11(79) 9(56) n.s
Parasitemia
n (% positive)
17(68) 4(13) < 0.0001 4(29) 0(0) < 0.0001
LDH (U/l)
[SEM] **
467 (19.1) 1378(165.1) < 0.0001 1716(236.2) 994.6(231.3) < 0.0001
EBV viral load (Log copies/ml)[SEM] .996 (0.36) 3.552(0.26) < 0.0001 3.32(0.308) 3.81(0.407) 0.0483
*Data are presented as medians (in brackets are the 25th and 75th percentiles). a Mann-Whitney test was used to determine differences in medians between
controls and BL patients and between patients with jaw and abdominal tumors. n.s denotes non significant p values. Abbreviation: BL, Burkitt’s Lymphoma; LDH,
lactose dehydrogenase; SEM, standard error of mean. **n = 30 BL patients
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Discussion
In our study, we set out to examine whether there was a
difference in EBV antibody responses in BL patients with
different clinical presentations, e.g. abdominal or jaw
tumors. In addition, we wanted to examine whether there
were elevated Zta antibody levels in BL patients relative
to age-and gender-matched controls. We observed signif-
icantly higher levels of antibody against Zta IgG in all BL
patients compared to malaria-exposed matched controls
and significantly higher levels of Zta IgG in children with
abdominal tumors compared to children with jaw
tumors. These data suggest that the underlying clinical
differences observed in site of BL presentation could be
potentially related to differences in EBV biology.
A defining characteristic of patients with nasopharyngeal
carcinoma (NPC), another EBV-associated malignancy, is
elevated anti-Zta IgG and plasma DNA levels [24]. Our
data extend these observations to BL, where we observed
Figure 1 P. falciparum-specific IgG in controls (n = 25) versus children presenting with BL (n = 32). Plasma was diluted at 1:6400 and
tested using a Luminex Bead Based array. Specific malaria antigens were (A) MSP1 3D7-specific IgG, (B) MSP1 FVO-specific IgG, (C) AMAI 3D7-
specific IgG, (D) AMA1 FVO-specific IgG and (E) LSA1-specific IgG. The mean flourescence intensity (MFI) of 75 of Luminex beads for each of the
antigen tested is indicated on the y-axis. P values of Mann-Whitney U tests are indicated in the figures. Horizontal bars represent median values
per each study population.
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significantly elevated anti-Zta IgG as well as anti-VCA IgG
and plasma viral loads in BL patients, relative to controls.
Of note is that the elevated Zta antibody levels correlated
with elevated viral DNA in the plasma. That both of these
antibodies to EBV lytic antigens and viral DNA were high
could be linked to increased viral re-activation in the
tumors or to increased viral re-activation from latently-
infected cells preceding the emergence of the malignancy.
This latter possibility is supported by a previous study
demonstrating that elevated anti-VCA antibodies in chil-
dren precedes the emergence of BL [14]. The former is
supported by evidence of EBV lytic gene expression in a
subset of cells within endemic BL tumors [11,25-27] and,
thus, could lead to elevated plasma viral loads following
release of virus from lytically-infected cells. What is sur-
prising is that there is no difference in levels of EAd anti-
bodies between controls and patients suggesting that the
correlation between elevated plasma EBV DNA and EBV
lytic re-activation is complex. No significant differences in
EBNA-1 antibody levels between cases and controls were
observed, consistent with our previous study on EBNA-1
antibody levels in BL patients using an ELISA-based
method [28].
Interestingly, differences in humoral immune responses
against EBV have also been reported under a variety of
different pathological conditions. For example, in HIV
patients, anti-VCA IgG correlates with EBV viral loads,
while in solid-organ transplant patients, viral load corre-
lates with both anti-EA and VCA IgG titers [29,30].
Moreover, within a single EBV protein, i.e. Zta, different
epitope responses have been described for different EBV-
linked disease entities, such as infectious mononucleosis,
NPC and non-Hodgkin lymphoma [31]. Further studies
are needed to understand the nature of EBV persistence
and re-activation in patients with EBV-associated malig-
nancies to determine if there are underlying alterations
in the pattern of EBV persistence that might precipitate
or predict the emergence of a malignant clone.
We found that BL patients with abdominal tumors
had higher levels of both anti-Zta IgG and plasma DNA
levels compared to patients presenting with tumors in
the jaw. Although the mechanisms that lead to the ele-
vated anti-Zta IgG and plasma DNA levels in the
abdominal tumor patients is still unclear, it could result
from increased tumor burden in this group, which is
indicated by the higher plasma LDH levels observed in
these patients. In NPC, tumor burden has also been
associated with elevated anti-Zta IgG and plasma DNA
levels [32]. However, the question as to why there are
also no concomitant increases in VCA or EAd IgG
Figure 2 EBV-specific IgG in controls compared to BL patients. Plasma from BL patients (n = 32) and controls (n = 25) was diluted at 1:6400
and tested using a Luminex Bead Based array. Specific EBV antigens were (A) Zta-specific IgG, (B) EAd-specific IgG, (C) VCA-specific IgG, (D)
EBNA1-specific IgG. The MFI of 75 of Luminex beads for each of the antigen tested is indicated on the y-axis. P values of Mann-Whitney U tests
are indicated in the figures. Horizontal bars represent median values per each study population.
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Figure 3 EBV-specific IgG in BL patients with jaw tumors (n = 14) and abdominal tumors (n = 16). Plasma was diluted at 1:6400 and
tested using a Luminex Bead Based array. Specific EBV antigens were (A) Zta-specific IgG, (B) EAd-specific IgG, (C) VCA-specific IgG, (D) EBNA1-
specific IgG. The MFI of 75 of Luminex beads for each of the antigen tested is indicated on the y-axis. The differences between two study
populations were compared using Mann-Whitney U test. p values of Mann-Whitney U tests are indicated in the figures. Horizontal bars represent
median values per each study population.
Figure 4 EBV viral load in BL patients and controls. PlasmaEBV viral loads were determined by Q-PCR and the values obtained were log-
transformed. (A) The plasma EBV viral loads were significantly higher in BL patients (n = 32) compared to the controls (p < 0.0001), (B) Plasma
EBV viral loads were significantly higher in patients presenting with abdominal tumors (n = 16) compared to jaw tumor patients (n = 14) (p <
0.0337). The differences between the two study populations were compared using Mann-Whitney U test. p values of Mann-Whitney U tests are
indicated in the figures. Horizontal bars represent median values per each study population.
Asito et al. Infectious Agents and Cancer 2010, 5:13
http://www.infectagentscancer.com/content/5/1/13
Page 6 of 10
levels in the patients presenting with abdominal tumors,
need to be addressed. In one study of BL, only mRNA
from Zta could be detected in the tumors but not
mRNA from another lytic transcript [25] suggesting that
there is an abortive lytic cycle in the tumors.
Chronic exposure of children to P. falciparum malaria
has been etiologically linked to Burkitt’s lymphoma
(reviewed in [3,4,14]). In support of these previous stu-
dies, two recent case control studies demonstrated that
BL cases had elevated anti-malaria antibody titers com-
pared to controls [8,15]. However, in contrast to these
studies, we found no differences in IgG levels to a broad
panel of pre-erythrocytic and erythrocytic antigens from
the two common circulating P. falciparum strains (3D7
and FVO) in BL patients and controls. Discrepancies
between these studies and our current findings may be
attributed to differences in study design. In our study,
we used controls from an area that has high incidence
of BL and experiences persistent P. falciparum transmis-
sion [7], while in the previous studies, the controls were
sick children presenting at the hospital with malignan-
cies and non-malignant conditions and were from pri-
marily urban areas as compared to the cases [8,15]. We
chose a population-based control group because most
children admitted to the Nyanza Provincial General
Hospital for non-malignant illness are from Kisumu city
whereas the children with BL are typically from rural
regions within the Province [33]. This was true for our
cohort as most of the BL patients in the current study
were from rural settings. Thus, since both our cases and
controls are from rural areas where malaria burden is
higher than in urban areas, it is more likely that our
cases and controls have similar exposure to P. falci-
parum. This could have, however, resulted in over-
matching of cases to controls and limited our ability to
identify differences in P. falciparum antibody responses.
A larger population based case-control study is clearly
needed to resolve the differences between our small
study and the hospital case-control studies done in
Uganda and Malawi [8,15].
Conclusions
Children presenting with abdominal BL have elevated
plasma EBV DNA, paralleled by elevated IgG levels to
Zta, compared to children presenting with jaw tumors,
suggesting differences in underlying patterns of EBV
replication. Whether BL presenting in the abdomen is a
different clinical entity will require more detailed studies
of the tumors themselves.
Methods
Study population
During the period from August 2007 and September
2008, we prospectively enrolled 34 children presenting
with endemic Burkitt’s lymphoma at the Nyanza Provin-
cial General Hospital, Kisumu, Kenya. Nyanza Provincial
General Hospital is located in Kisumu city. As the lar-
gest hospital in the Province, it provides out-patient and
in-patient services, and maintains its own pathology and
radiology laboratories. The hospital is the referral center
for childhood cancer cases and is the only medical facil-
ity that maintains chemotherapeutic treatment for BL in
the region. The BL patients in this study predominantly
came from all Districts in Nyanza Province (e.g. Siaya,
Homa Bay, Kisumu, Migori, Kisii) as well as some Dis-
tricts in Western Province (e.g. Kakamega, Vihiga,
Nandi, and Busia). With the exception of Kisumu Dis-
trict which includes Kisumu City, these Districts are
predominantly rural. BL diagnosis was based on histolo-
gical assessment of fine needle aspirate (FNA) stained
with May-Grunewald Giemsa. Assessment was done by
both the clinical cytologist and pathologist at NPGH.
One patient was diagnosed with acute leukemia and was
excluded from further analysis. Routine HIV testing is
done on all patients admitted to NPGH. HIV exposure
was determined in venipuncture blood using two rapid
serological assays: Unigold (Trinity Biotech, Bray,
County Wicklow, Ireland) and Determine (Abbott
Laboratories, Chicago, Illinois, USA). One BL patient
was HIV+ and was excluded from further analysis. All
blood samples were taken from these patients prior to
chemotherapy.
Controls were identified from Kanyawegi village along
the shores of Lake Victoria in Kisumu West district,
Nyanza province, after physical and clinical evaluation
of their health status by the study clinician officers.
Kanyawegi is in a rural district that has a high incidence
rate of BL and experiences persistent P. falciparum
transmission [7]. After informed consent, blood samples
were also collected from 25 healthy age-and gender-
matched children (herein referred to as controls).
Microscopic investigation of P. falciparum parasites
Parasitemia was determined at time of blood collection
by performing a thick smear and staining with 5%
Giemsa. The slides were examined by two microscopists,
any discrepancies in the slide reading were resolved by a
third microscopist. Parasite density was expressed as the
number of asexual P. falciparum per μL of blood assum-
ing a leukocyte count of 8000 per μL.
Blood collection and processing
Ethical approval for this study was given by the Kenya
Medical Research Institute (KEMRI) Ethical Review
Committee, Institutional Review Board for Human stu-
dies at the Case Western Reserve University (Dr. Moor-
mann’s institutional affiliation at time of sample
collection) and SUNY Upstate Medical University. After
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informed consent was given by the study participants’
parent or guardians, finger prick blood was collected in
EDTA tubes and measurements of hemoglobin levels
were determined using a portable b-haemoglobin photo-
meter (Hemocue AB Angelholm, Sweden). Additionally,
2-5 ml of venous blood was drawn from both BL
patients and controls. Ficoll density gradient centrifuga-
tion of blood was done within 1 hour of blood collec-
tion; the plasma was removed for subsequent serologic
or virologic analysis. The aliquots were then stored in a
-80°C freezer. Biochemical analysis of lactate dehydro-
genase (LDH) levels to determine tumor burden was
carried out on frozen plasma samples using Selectra E
auto analyzer (Vita lab, Amsterdam, The Netherlands)
following standard biochemistry procedures using
Fortress diagnostics kits (Fortress Diagnostics Limited,
Belfast, UK).
P. falciparum and EBV antigens
P. falciparum-specific IgG was detected using five of
recombinant P. falciparum antigens, MSP-1(3D7), MSP-
1 (FVO), AMA-1 (3D7), AMA-1 (FVO) and LSA-1 (in
collaboration with Dr. Carole Long for MSP-1, Dr.
David Lanar for AMA-1, and Dr. Sheetij Dupta for
LSA-1) and EBV-specific IgG was determined using four
synthetic peptides representing immuno-dominant epi-
topes of the viral capsid antigen (VCA), EBV nuclear
antigen 1 (EBNA1), diffuse early antigen complex (EAd)
and immediate early protein (Zta) antigens of EBV. The
definition and serological use of these EBV peptide
reagents has been described before [17,18]. In early stu-
dies we defined that the predominant response to Zta in
BL patients was directed against the N-terminal domain,
spanning amino acids 1-44 (Middeldorp, unpublished
data). Therefore, this domain was used as synthetic Zta
antigen throughout this study.
Luminex assay
In order to detect P. falciparum and EBV-specific IgG
against a panel of peptides, we used the previously
described protocol [15]. Briefly, different amounts of
peptides or proteins were coupled with 1 × 106 pre-acti-
vated carboxylated microspheres (Luminex, Austin TE,
USA) in 500 μl of 100 mM MES pH 6.0 buffer (pep-
tides) or 50 mM MES pH 5.0 buffer (proteins). The
beads were then washed and stored in PBS, 0.1% BSA,
0.002% Tween-20, 0.05% Sodium Azide, pH 7.4 at 4°C
until use. The amounts of peptides used per 500 μL
coupling reaction were 20 μg for VCA, EBNA1 and Zta,
and 50 μg was used for EAd. The amounts of recombi-
nant malaria proteins per 500 μL reaction were 10 μg
for the AMA-1 and MSP-1 antigens, and 20 μg for
LSA-1. During the development of the assay, several
sample dilutions were tested (ranging from 1:35 to
1:51,200) to determine the best dilution for testing IgG
levels to different antigens in the test panel. It appeared
that the Luminex assay was more sensitive than ELISA
assays performed in parallel, and that in order for a
majority of results to fall within the linear part of a stan-
dard curve (e.g. dilutions of a positive control sample
versus fluorescent units) a dilution of 1:6400 was most
appropriate. Therefore, we tested all samples at the typi-
cal 1:100 dilution as well as 1:6400. During the analysis,
it appeared that indeed the 1:6400 dilution allowed for
better distinction between high and low antibody levels
than the 1:100 dilution. Thus, antigen specific IgG was
measured by incubating 1000 beads of each antigen per
well with plasma diluted 1:100 and 1:6400 in a final
volume of 100 μl, but the results of the 1:6400 dilution
were used in the final analysis. After washing, a 1:200
dilution of PE-conjugated Goat F(ab)2 anti Human IgG
(Biosource, Camarillo, CA) was added. At least 75 beads
of each antigen were then acquired on a Bioplex reader
(Bio Rad, Hercules, CA). Sera from North Americans
who had no prior exposure to P. falciparum were used
as negative controls while pooled plasma from indivi-
duals who were constantly positive for P. falciparum
antibodies were used as positive controls for P. falci-
parum antigens. In addition, EBV-seronegative and -ser-
opositive controls were used in each plate. The results
of the assay were expressed in Mean Fluorescent Inten-
sity (MFI) of at least 75 beads for each P. falciparum
and EBV antigen tested.
Quantitative PCR to quantify EBV DNA
DNA was extracted from 200 μl plasma using Qiagen
DNAeasy kit (Qiagen, Valencia, CA) according to the
manufacturers’ protocol. DNA was eluted off the col-
umn in an equivalent volume of H20 and stored at
-20°C. Previously designed primers and probes that
detect a 70 bp region of the EBV BALF5 gene were
used [34]. The quantitative (Q)-PCR cycle was as fol-
lows: 2 min at 50°C, 10 min at 95°C, 42 cycles of 15 sec
at 95°C and 1 min at 60°C using thermal cycler model I
Cycler™ optical module (BioRad Laboratories, Hercules,
CA). IQ SuperMix (BioRad Laboratories, Hercules, CA)
was used for all reactions. To generate a standard curve,
we used an EBV positive plasmid generated from the
PCR product. The viral loads were log-transformed and
then calculated based on EBV genome copies/ml.
Statistical analysis
GraphPad prism version 5 (GraphPad Software, Inc, La
Jolla, CA) was used for all the data analysis. Differences
in the levels of P. falciparum and EBV-specific IgG
levels between controls and BL patients were compared
using Mann-Whitney U test. The same test was used to
compare both antigen-specific IgG levels and viral loads
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between children presenting with jaw and abdominal
tumors. Across group comparisons of antigen-specific
IgG levels and viral loads in controls, BL patients with
jaw and abdominal tumors, was carried out using Krus-
kal-Wallis test. The association between categorical vari-
ables for healthy and BL patients was assessed using
Fisher’s exact test. Two-way ANOVA was used to evalu-
ate the association between antigen-specific IgG levels
with diseases status. Correlations between antigen speci-
fic IgG levels and viral load were done using Spearman’s
Rho test. p ≤ 0.05 was considered statistically significant.
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